Cardio Diagnostics Holdings Inc. Common stock
CDIO XNASAbout Cardio Diagnostics Holdings Inc. Common stock
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
Key Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.7K | $-1,788,158 | $-0.63 |
| FY 2025 | $14.8K | $-6,498,167 | $-3.71 |
| Q3 2025 | $2.9K | $-1,714,536 | $-0.98 |
| Q2 2025 | $7.5K | $-1,683,199 | $-0.97 |
Earnings & Analyst Ratings
TickerDaily Coverage
Get CDIO Alerts
Stay ahead with breaking news, price alerts, and expert analysis on Cardio Diagnostics Holdings Inc. Common stock.